Inhibition of selective adhesion molecules in treatment of inflammatory bowel disease (Q38053495)

27 August 2017

title

Inhibition of selective adhesion molecules in treatment of inflammatory bowel disease (English)

1 reference

inflammatory bowel diseases

27 August 2017

main subject

0 references

author name string

Nilanjan Ghosh

series ordinal

1

1 reference

27 August 2017

Rituparna Chaki

series ordinal

2

1 reference

27 August 2017

Subhash C Mandal

series ordinal

3

1 reference

27 August 2017

publication date

1 October 2012

1 reference

International Reviews of Immunology

27 August 2017

published in

1 reference

27 August 2017

volume

31

1 reference

27 August 2017

issue

5

1 reference

27 August 2017

page(s)

410-427

1 reference

Emerging drugs to treat Crohn's disease

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.690794

Intestinal epithelial cells in inflammatory bowel diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.690794

Rheumatic manifestations of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.690794

A gut feeling of the PXR, PPAR and NF-kappaB connection

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.690794

Inflammatory bowel disease: beyond the boundaries of the bowel

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.690794

Mechanisms and efficacy of immunobiologic therapies for inflammatory bowel diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.690794

Th17 cells: interactions with predisposing factors in the immunopathogenesis of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.690794

Use of biological molecules in the treatment of inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.690794

Targeting leukocyte integrins in human diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.690794

The transmembrane domains of L-selectin and CD44 regulate receptor cell surface positioning and leukocyte adhesion under flow

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.690794

Leukocytes roll on a selectin at physiologic flow rates: distinction from and prerequisite for adhesion through integrins.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.690794

Physiological basis for novel drug therapies used to treat the inflammatory bowel diseases. I. Immunology and therapeutic potential of antiadhesion molecule therapy in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.690794

Integrin structure, activation, and interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.690794

Anti-adhesion molecule therapy for inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.690794

Breaking the integrin hinge. A defined structural constraint regulates integrin signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.690794

Integrin structure: new twists and turns in dynamic cell adhesion

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.690794

Role of beta7 integrins in intestinal lymphocyte homing and retention

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.690794

The pathophysiologic role of alpha 4 integrins in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.690794

Human G protein-coupled receptor GPR-9-6/CC chemokine receptor 9 is selectively expressed on intestinal homing T lymphocytes, mucosal lymphocytes, and thymocytes and is required for thymus-expressed chemokine-mediated chemotaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.690794

Selective generation of gut tropic T cells in gut-associated lymphoid tissue (GALT): requirement for GALT dendritic cells and adjuvant.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.690794

Chemokines in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.690794

Selective imprinting of gut-homing T cells by Peyer's patch dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.690794

The lymphocyte metalloprotease MDC-L (ADAM 28) is a ligand for the integrin alpha4beta1

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.690794

Interactions of thrombospondins with alpha4beta1 integrin and CD47 differentially modulate T cell behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.690794

The role of junctional adhesion molecules in vascular inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.690794

Junctional adhesion molecule 1 regulates epithelial cell morphology through effects on beta1 integrins and Rap1 activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.690794

Junctional adhesion molecule (JAM)-B supports lymphocyte rolling and adhesion through interaction with alpha4beta1 integrin

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.690794

Attenuation of colitis in the cotton-top tamarin by anti-alpha 4 integrin monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.690794

Novel model of TH2-polarized chronic ileitis: the SAMP1 mouse.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.690794

L-selectin, alpha 4 beta 1, and alpha 4 beta 7 integrins participate in CD4+ T cell recruitment to chronically inflamed small intestine

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.690794

In vivo demonstration of T lymphocyte migration and amelioration of ileitis in intestinal mucosa of SAMP1/Yit mice by the inhibition of MAdCAM-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.690794

Blockade of PSGL-1 attenuates CD14+ monocytic cell recruitment in intestinal mucosa and ameliorates ileitis in SAMP1/Yit mice

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.690794

Targeted therapies in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.690794

Overview of biologic therapy for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.690794

A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.690794

Natalizumab for active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.690794

Natalizumab Induction and Maintenance Therapy for Crohn's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.690794

Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.690794

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.690794

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.690794

Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.690794

Progressive multifocal leukoencephalopathy and apoptosis of infected oligodendrocytes in the central nervous system of patients with and without AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.690794

Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.690794

Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.690794

Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.690794

Antibody-based therapeutics to watch in 2011

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.690794

Alicaforsen therapy in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.690794

Correlation of toxicity and pharmacokinetic properties of a phosphorothioate oligonucleotide designed to inhibit ICAM-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.690794

A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.690794

A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.690794

A phase II dose ranging, double-blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.690794

Bioavailability and therapeutic activity of alicaforsen (ISIS 2302) administered as a rectal retention enema to subjects with active ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.690794

Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.690794

Expression of CD45RB functionally distinguishes intestinal T lymphocytes in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.690794

A humanized monoclonal antibody targeting the β7 integrin selectively blocks intestinal homing of T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.690794

Demonstration of functional role of TECK/CCL25 in T lymphocyte-endothelium interaction in inflamed and uninflamed intestinal mucosa

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.690794

Blocking lymphocyte localization to the gastrointestinal mucosa as a therapeutic strategy for inflammatory bowel diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.690794

Chemokines in lymphocyte trafficking and intestinal immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.690794

Homing of immune cells: role in homeostasis and intestinal inflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.690794

CCL25 and CCL28 promote alpha4 beta7-integrin-dependent adhesion of lymphocytes to MAdCAM-1 under shear flow

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.690794

Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.690794

Cell adhesion and cancer: is there a potential for therapeutic intervention?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.690794

The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.690794

Promising emerging therapies for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.690794

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.690794

MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.690794

The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: a randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.690794

10.3109/08830185.2012.690794

21 January 2018

Identifiers

DOI

1 reference

27 August 2017

1 reference